ที่บชง Page 1 of 5 Ref. Bor Chor Ngor 0413/2019 12 November 2019 Subject: Management Discussion and Analysis for the Third Quarter ended 30 September 2019 To President The Stock Exchange of Thailand

15 May 2019 Subject: Management Discussion and Analysis for the 3-Month Period Ended March 31, 2019 To: Directors and Managers The Stock Exchange of Thailand Halcyon Technology Public Company Limited

of Company Secretary, the Establishment of New Subsidiary and Subsidiary to Purchase Drug Care Company Limited (Revise no. 2) 10/11/2021 09:27 Notification of the resignation of Chairman of the Audit

Income for the year 2019 per following table: (THB) Million 2019 2018 Change %Change Total Revenues 531.73 538.96 (7.23) (1) Total Expenses (497.06) (488.86) 8.20 2 Shares of Profits (Loss) (46.23) 26.72

the disclosure should take into account on certainly and completeness on information of such transaction. In case of cancellation or change on the key terms, this shall affect to the Company, relevant

. Cost of funds for 1Q19 remained stable at 2.3% comparing to 1Q18. For the three-month period ended Consolidated Change Mar 31, 2019 Mar 31, 2018 Baht million % Interest expense 1,386 1,143 242 21.2

February 2020 Subject: Clarification of the operating results for the year ended 31 December 2019, change of rate more than 20 percent To: Director and Manager The Stock Exchange of Thailand Ocean Commerce

. DOD017/2562 May 8, 2019 Re: Management’s Discussion and Analysis (MD&A) of the Consolidated Financial Results for Quarter 1 of 2019 To: The President The Stock Exchange of Thailand DOD Biotech Public

- Total revenues amounted to 271.4 million baht, same as last year. Chemicals Business grew 4%, from 227.9 to 236.5 million baht. Other income increased from 2.8 million baht to 4.6 million baht attributed

improving the overall licensing scheme and provided observations and suggestions on important issues. The SEC has incorporated such feedbacks to revise the principles for more appropriateness. For example